Anti- FcRH5/IRTA2/CD307e Antibody (Cevostamab)

Introduction

Cevostamab (BFCR4350A; RG6160; RO7187797) is a humanized, IgG1-based BsAb that targets the membrane-proximal extracellular domain of FcRH5 on multiple myeloma (MM) cells and CD3 on T cells. In addition, Cevostamab promotes the formation of effective synapses and enhances the cytotoxic activity of T cells against MM tumor cells.

Product parameters

Alternative Names	BFCR4350A, RO-7187797, RG6160
Target Accession	Q96RD9
Target	FcRH5 / IRTA2 / CD307e
CAS number	/
Molecular Weight	145 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	Immobilized human IRTA2 His at 2 ug/mL can bind Anti- FcRH5/IRTA2/CD307e Antibody (Cevostamab), EC50=0.007032 ug/mL.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 μM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80℃
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.

APExBIO Technology
www.apexbt.com
7505 Fannin street, Suite 410, Houston, TX 77054.
Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com